Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Oral and Maxillofacial Surgery
  •  Bariatric Surgery
  •  Transplant Surgery
  •  Breast Surgery
  •  Vascular Surgery
  •  General Surgery
  •  Cardiovascular Surgery
  •  Plastic Surgery


Citation: Clin Surg. 2019;4(1):2438.Research Article | Open Access

Parecoxib Prevents Postoperative Pain after Radiofrequency Ablation for Liver Cancer: A Propensity Score Matching Analysis

Jian-Cong Chen, Jun-Cheng Wang, Yao-Jun Zhang, Li Xu, Jin-Bin Chen, Yang-Xun Pan, Ying-Qin Zhu, Min-Shan Chen and Zhong-Guo Zhou

Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, China
Both authors contributed equally to this work

*Correspondance to: Zhong-Guo Zhou 

 PDF  Full Text DOI: 10.25107/2474-1647.2438


Background: Pain is one of the most dominating adverse effects in radiofrequency ablation therapy. The purpose of this study is to evaluate the role of parecoxib sodium on pain management in patients with liver cancer undergoing radiofrequency ablation.
Methods: A total of 186 patients diagnosed as liver cancer (including primary cancer 122 cases and metastasis lesion 64 cases) and treated with radiofrequency ablation at Sun Yat-sen University Cancer Center between April 2015 and January 2016 were retrospectively reviewed. About 111 patients achieved the inclusion criteria and were divided into the parecoxib group (experimental group; n=56) and the non-parecoxib group (control group, receiving 0.9% sodium chloride; n=55), according to whether or not the medication was applied. Post-operative pain, vomiting, body temperature, changes in hepatic function, and duration of postoperative hospitalization time were compared between the two groups.
Results: After the propensity score matching analysis, the parecoxib group had suffered less severe pain on postoperative day 0, day 1 and day 2 (with P<0.000, 0.001 and 0.0041, respectively), compared with the non-parecoxib one, along with a lower ALT and CRP levels (177.0 ± 88.0 vs. 327.7 ± 387.1 U/L, P<0.016, and 20.0 ± 29.0 vs. 49.7 ± 44.1 mg/L, P<0.001, respectively), and an insignificant shorter postoperative hospitalization time was witnessed, though not significantly (2.4 ± 0.7 vs. 2.6 ± 0.6 days, P=0.186).
Conclusion: This research illustrated that the preemptive application of parecoxib can remarkably relieve postoperative discomfort, especially controlling post-operative pain, reducing hepatic inflammation, and shortening post-operative hospital stay after radiofrequency ablation for liver cancer.


Parecoxib; Postoperative complication control; Pain management; Radiofrequency ablation

Cite the article

Chen J-C, Wang J-C, Zhang Y-J, Xu L, Chen J-B, Pan Y-X, et al. Parecoxib Prevents Postoperative Pain after Radiofrequency Ablation for Liver Cancer: A Propensity Score Matching Analysis. Clin Surg. 2019; 4: 2438.

Search Our Journal

Journal Indexed In

Articles in PubMed

Mesh Sprayer Device with Liquefied Mesh Delivery System: Proposed Alternative for Currently Available Meshes in Hernia Repair and Supplement to Abdominal Closure
 PubMed  PMC  PDF  Full Text
Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Effect of Home Blood Pressure Telemonitoring Plus Additional Support on Blood Pressure Control: A Randomized Clinical Trial
 Abstract  PDF  Full Text
Step-by-Step Procedure to Test Photoelectric Dye-Coupled Polyethylene Film as Retinal Prosthesis to Induce Light- Evoked Spikes in Isolated Retinal Dystrophic Tissue of rd1 Mice
 Abstract  PDF  Full Text
View More...